AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$2.56
−$0.02 (−0.97%) 4:00 PM ET
Pre-market$2.57
+$0.01 (+0.59%) 4:23 PM ET
Prev closePrevC$2.58
OpenOpen$2.47
Day highHigh$2.66
Day lowLow$2.47
VolumeVol556,506
Avg volAvgVol745,757
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$284.74M
P/E ratio
-1.84
FY Revenue
$21.05M
EPS
-1.39
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
ALEC
Alector, Inc.
ALEC shows meaningful price recovery over the past year with the stock more than doubling from its 12‑month low and trading above key short-term moving averages, while still well below the 52‑week high. At the same time, fundamentals remain deeply loss-making with sharply contracting revenue and highly negative margins and free cash flow. Valuation multiples appear elevated relative to current earnings and cash generation, and ongoing legal and clinical-trial overhangs from a failed Phase 3 program add to risk.
Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034
The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.
Developing Latozinemab (AL001) for frontotemporal dementia and AL101 (GSK4527226) for early Alzheimer's. The company completed Phase II enrollment in April 2025 and has advanced with key regulatory designations, addressing unmet needs in non-Alzheimer's dementia subtypes.
NegativeGlobeNewswire Inc.• The Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm
Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.
ALECclinical trialfrontotemporal dementiashareholder lawsuitdrug development
Sentiment note
Failed clinical trial for key drug candidate, significant stock price decline, and potential legal action from shareholders indicate substantial negative business impact
NegativeGlobeNewswire Inc.• The Association For Frontotemporal Degeneration
Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic
Biotechnology company Alector announced that its drug latozinemab did not meet safety and efficacy criteria in a Phase 3 clinical trial for treating frontotemporal dementia (FTD) caused by GRN gene variants. Despite increasing progranulin protein levels, the drug did not slow disease progression.
Drug failed primary clinical trial endpoints, leading to discontinuation of trial and extension studies
PositiveGlobeNewswire Inc.• N/A
Alector to Participate in Upcoming Healthcare Conferences
Alector, a late-stage clinical biotechnology company, announced that it will participate in upcoming investor conferences, where it will present its therapies for neurodegenerative diseases.
The article highlights Alector's participation in upcoming investor conferences, which suggests the company is actively engaging with the investment community and promoting its therapies for neurodegenerative diseases, indicating a positive outlook.
PositiveGlobeNewswire Inc.• N/A
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
Alector, a late-stage clinical biotechnology company, provided an update on its pipeline, including the anticipated topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation, and the ongoing PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease. The company also highlighted its preclinical and research pipeline, including programs leveraging its Alector Brain Carrier technology.
The article highlights Alector's progress in its clinical trials, preclinical pipeline, and financial position, indicating the company is well-positioned to continue advancing its programs for neurodegenerative diseases.
PositiveGlobeNewswire Inc.• N/A
Alector to Participate in Upcoming Healthcare Conferences
Alector, a clinical-stage biotechnology company, announced that it will participate in several upcoming investor conferences, including the Morgan Stanley 22nd Annual Global Healthcare Conference, the H.C. Wainwright 26th Annual Global Investment Conference, and the 2024 Cantor Global Healthcare Conference.
ALECAlectorinvestor conferencesbiotechnology
Sentiment note
The article highlights Alector's participation in upcoming investor conferences, which suggests the company is actively engaging with the investment community and is likely in a strong position to showcase its progress and future plans.
PositiveGlobeNewswire Inc.• N/A
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
Alector presented baseline characteristics for the INVOKE-2 Phase 2 clinical trial of its TREM2 agonist AL002 in early Alzheimer's disease. The trial enrolled a representative population, allowing for testing of the novel TREM2 agonist.
The article presents positive data on Alector's INVOKE-2 clinical trial, indicating that the trial enrolled the intended population and will allow for effective testing of the TREM2 agonist AL002.
UnknownZacks Investment Research• Zacks Equity Research
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
PRTAALEC
UnknownGlobeNewswire Inc.• Alector, Inc.
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
ALECCalendar of Events
UnknownGlobeNewswire Inc.• Alector, Inc.
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
ALECCalendar of EventsHealthConference Calls/ Webcasts
UnknownZacks Investment Research• Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ALECEQ
UnknownZacks Investment Research• Zacks Equity Research
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALECTSVT
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
